Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nexgel Q3 2026 Results: Net Loss of $1.11M, Loss Widens

NEXGEL, INC. reported a net loss of $5.68 million for the nine months ended September 30, 2026, compared to $2.03 million in the prior year, driven by significant increases in selling, general, and administrative expenses. Total assets grew to $23.90 million following a major $12.34 million increase in intangible assets, while the company underwent a 1-for-20 reverse stock split in October 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3.22.9
Gross profit1.11.2
Profit before tax-1.1-0.6
Net income-1.1-0.7
EPS (diluted, $ a share)$-2.28$-1.64

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+8.4%
Gross margin35.4%
Operating margin-79.9%
Source

10-Q filed with the SEC, NASDAQ: NXGL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nexgel, Inc.: key numbers

Share price
$3.93Close, Nov 16
Market cap
$2.11M
Shares outstanding
536.11KLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nexgel, Inc.

All →
9:59 PM ET Form 4
Insider Buying

Nexgel Interim CEO Brian Joseph Kieser Buys $733K of Stock

Brian Joseph Kieser, Interim CEO, bought 133,216 shares of Nexgel, Inc. at $5.50 a share, worth $733K in total on Nov 10, 2026. Shares held after the trade: 133,216.

Value
$733K
Shares
133,216
Price
$5.50
Role
Interim CEO
Trade date
Nov 10, 2026
9:58 PM ET Form 4
Insider Buying

Nexgel Insider steven mark glassman Buys $25K of Stock

steven mark glassman bought 4,546 shares of Nexgel, Inc. at $5.50 a share, worth $25K in total on Nov 10, 2026. Shares held after the trade: 12,379 (+58.0%).

Value
$25K
Shares
4,546
Price
$5.50
Holding change
+58.0%
Trade date
Nov 10, 2026
9:03 AM ET 8-K
M&A Deal

Nexgel M&A Deal with Fountainhead LifeSciences

NEXGEL announced a strategic recapitalization and update on a potential merger with Fountainhead LifeSciences, including its affiliates Sequence LifeScience and NVISION Biomedical Technologies. As part of the plan, holders of $14.125 million in convertible notes (95% of outstanding principal) agreed to convert their debt into common stock at $5.50 per share, contingent upon the completion of the merger.

Counterparty
Fountainhead LifeSciences
4:39 PM ET 8-K
Reverse Stock Split

Nexgel Reverse Stock Split

NexGel, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective October 12, 2026. The split aims to consolidate every twenty shares into one share to adjust the per-share trading price while maintaining the par value at $0.001. The common stock will continue to trade on The Nasdaq Capital Market under the ticker 'NXGL' with a new CUSIP number.

4:16 PM ET 8-K
Investor Presentation

Nexgel Investor Presentation

NexGel, Inc. has released a new shareholder update presentation titled 'Strategic Review & Proposed Platform Reorganization.' The presentation outlines the company's strategic direction and proposed changes to its business platform to drive future growth.

5:21 PM ET 8-K
Reverse Stock Split

Nexgel Reverse Stock Split

NexGel stockholders approved an amendment to the Certificate of Incorporation to effect a discretionary reverse stock split at a ratio between 1-for-2 and 1-for-20. Stockholders also approved increasing the number of authorized shares of common stock from 25 million to 150 million.

Term
within one year

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.